Conference abstract · 23 Oct 2019
Conference abstract
Dendritic vaccine delivery systems
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Subunit vaccines that contain the minimal microbial components necessary to stimulate appropriate immune responses have the potential to overcome allergic response or autoimmunity that can result from using classical vaccines. We developed new delivery systems by combining the adjuvant and antigenic peptide epitopes into one chemically bonded dendritic entity. The presentation of epitopes on the nanoparticles surface was optimized to elicit a strong immune response in mouse models. Infection with Group A Streptococci (GAS), one of the most common and widespread human pathogens, can result in a broad range of diseases, with the potential to develop acute and post-infectious rheumatic fever and rheumatic heart disease. Immunity to GAS relies on the production of opsonic antibodies specific to the hyper-variable N-terminal and conserved C-terminal regions of the coiled-coil α-helical M protein, a GAS major virulence factor. To improve vaccine delivery, we developed a self-adjuvnating lipid core peptide (LCP) dendrimer system that included the antigen, a T helper epitope, a carrier and the adjuvant within the same molecular entity. The system allowed the attachment of multiple copies of antigens. We investigated the structural requirements to elicit production of different antibodies (IgA, IgG) and assessed the influence of complex size on the level of antibody production. Recent developments in nanomedicine/vaccinology have identified that size and morphological characteristics of nanoparticle vaccines affect their efficacy. Preliminary investigations have demonstrated that polymer-based nanoparticles that displayed peptide epitopes on their surface induced very strong immune responses against those epitopes. We have also shown that this response was dependent on the size of the total construct. We explored the efficacy of nanoparticle vaccines using a Human Papillomavirus (HPV) model. HPV infection, most commonly HPV-16, is responsible for the vast majority of cases of cervical cancer, which is the second most common cancer in women worldwide. The development of therapeutic vaccines that eliminate HPV infected cells and eradicate established HPV-associated tumors would therefore be beneficial and desirable. We established a synthetic pathway to conjugate Human papillomavirus peptide antigens to the polymeric core to create macromolecular vaccine candidates to treat HPV-related cancers. These conjugates reduced tumor growth and eradicated established E7-expressing TC-1 tumors in mice after a single immunization, without the addition of an external adjuvant. We extended our vaccine delivery platform investigations by using Luteinizing Hormone-Releasing Hormone (LHRH) as antigen. An anti-LHRH vaccine aims to control the level of sex hormones FSH and LH by generating antibodies against LHRH in murine and ovine models. We have observed significant IgG antibody response after primary immunization without the use of additional adjuvant. The antibody response was enhanced and long-lasting when we co-administered commercial adjuvant AdjuVacTM with our LCP-LHRH vaccine formulation.
Subjects
Vaccines & ImmunisationAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 27 Jul 2015
A dendritic cell-targetted vaccine loaded with a glyceraldehyde-3-phosphate dehydrogenase peptide confers wide protection to listeriosis in susceptible and resistant mice
Article · 30 Jun 2025
Innovative Genetic Delivery Systems Transforming Modern Vaccination Strategies
Commentary · 14 Dec 2021
Vaccine Drug Delivery Systems: A Short Note
Conference abstract · 3 Jun 2019
The future of nucleic acid vaccines and non-viral delivery systems
More from this journal
The newest in Journal of Vaccines & Vaccination.
Article · 29 Aug 2026
Advancing Immune-Based Disease Management through Therapeutic Vaccines
Article · 29 Aug 2026
Advances in Adjuvant Development for Enhanced Vaccine Performance and Long-Term Immune Protection
Article · 20 Jun 2026
Herd Immunity and Its Role in Controlling Infectious Diseases
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Vaccines & Vaccination
- SubjectVaccines & Immunisation
- BylineArticles whose byline prints “Istvan Toth”
